<DOC>
	<DOCNO>NCT01271439</DOCNO>
	<brief_summary>This open , multicenter phase Ⅱ clinical trial . The purpose study evaluate acute toxicity efficacy cetuximab ( C225 ) combine IMRT + neoadjuvant chemotherapy advance T stage nasopharyngeal carcinoma . Besides , figure relationship patient outcome EGFR gene copy number , expression mutation .</brief_summary>
	<brief_title>Study Chemoradiotherapy Combined With Cetuximab Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologic diagnosis nasopharyngeal carcinoma Range 18～69 year old T34，N02，M0 ( AJCC 2009 ) KPS ≥ 80 Nonmetastatic disease WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L ALT AST ＜ 1.5×ULN、bilirubin ＜ 1.5×ULN 0Serum creatinine ＜ 1.5×ULN Distance metastasis Previously treat ( surgery，chemotherapy , radiation therapy，EGFR target therapy immunotherapy ) Second malignancy within 5 year Precious therapy investigational agent Uncontrolled seizure disorder serious neurologic disease ≥ Grade Ш allergic reaction drug include study Clinically significant cardiac respiratory disease Creatinine clearance &lt; 30ml/min Drug alcohol addition Do full capacity civil act Severe complication , active infection Concurrent immunotherapy hormone therapy diseases Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>